Related Experiment Video
Updated: Jul 11, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Leflunomide in psoriatic arthritis
1Abt. Rheumatologie, Medizinische Klinik II, Zentrum der Inneren Medizin, Klinikum der J.W. Goethe-Universität, Frankfurt am Main, Theodor Stern Kay 7, D-60590 Frankfurt am Main, Germany. kaltwasser@em.uni-frankfurt.de
Autoimmunity Reviews
|September 15, 2007
Summary
Leflunomide effectively treats psoriatic arthritis (PsA) by improving joint and skin symptoms. This study shows Leflunomide is a safe, well-tolerated, and affordable option for PsA patients.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is an inflammatory condition linked to psoriasis, affecting 5-30% of psoriasis patients.
- PsA often presents as asymmetrical joint inflammation, enthesitis, and dactylitis.
- T-cells are implicated in the immune pathology of both PsA and psoriasis.
Purpose of the Study:
- To evaluate the efficacy and safety of Leflunomide in treating active psoriatic arthritis.
- To assess Leflunomide's impact on both joint and skin manifestations of PsA.
Main Methods:
- A randomized, placebo-controlled, multicenter trial (TOPAS Study) was conducted.
- 20 mg/day oral Leflunomide was administered to patients with active PsA.
- Treatment outcomes were assessed using Psoriatic Arthritis Response Criteria (PsARC), modified ACR20, and PASI 50 at 24 weeks.
Main Results:
- Significant improvements were observed in PsARC, modified ACR20, and PASI 50 scores after 24 weeks of Leflunomide treatment.
- Leflunomide treatment demonstrated a favorable safety profile.
- Patients reported improved quality of life.
Conclusions:
- Leflunomide is an effective and well-tolerated treatment for active psoriatic arthritis.
- It offers a safe, relatively inexpensive therapeutic option for managing PsA joint and skin symptoms.
- Leflunomide improves quality of life in PsA patients.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...